A triple approach strategy for patients with locally advanced pancreatic adenocarcinoma.

Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review

“…[8][9][10] Thereafter, the authors decreased the RFA temperature to 90°C, resulting in a significant reduction in the rate of complications, particularly in rates of mesenteric and portal thrombosis, which represent typical thermal vein damage, 8 and duodenal damage. 11 In the study by Singh et al, no major procedure-related morbidity or mortality occurred; one patient developed a 2-cm asymptomatic pseudocyst. 12 Spiliotis et al reported biliary leak after RFA in two patients.…”

“…[8][9][10][12][13][14][15] The remaining five studies were included in the present review. [8][9][10][11][12][13][14][15] Four studies were prospective cohort studies 10,12,14,15 and one study was a retrospective cohort study. 13 The characteristics of the five included studies are summarized in Table 1.…”

“…14 The largest series, reported by Girelli et al, 10 cited an RFA-related morbidity of 15% and an RFA-related mortality of 3% in 100 patients with unresectable locally advanced pancreatic cancer. [8][9][10][11] Girelli et al 8 treated the first 25 patients with RFA at a temperature of 105°C; at this temperature a high complication rate was seen. [8][9][10] Thereafter, the authors decreased the RFA temperature to 90°C, resulting in a significant reduction in the rate of complications, particularly in rates of mesenteric and portal thrombosis, which represent typical thermal vein damage, 8 and duodenal damage.…”

Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer

“…Spiliotis and co-workers 33 reported a median survival between 13 and 19 months for eight patients treated with RFA and bypass surgery, and showed an improvement in survival following RFA of the pancreas compared with that in nine patients receiving best supportive care. In a larger cohort of 107 patients treated with RFA, median overall survival was 25⋅6 months 30 . Furthermore, these authors made a distinction in survival after RFA as initial and as secondary treatment, and showed a median survival of 14⋅7 versus 25⋅6 months (from the date of diagnosis to death) respectively.…”

“…A total of seven clinical studies were included of which four were prospective 28 -31 and two retrospective 32,33 ; one study 34 did not report on the design (Table S1, supporting information). Four studies 28 30 107…”